FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Blackman Samuel C. (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol Day One Biopharmaceuticals, Inc. [DAWN]										5. Relationship of Reporting Check all applicable) Director X Officer (give title below)			10% (Owner (specify	
395 OYSTER POINT BLVD, SUITE 217					3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022										Chief Medical Officer					
ı	(Street) SOUTH SAN FRANCISCO CA 94080				4. If Amendment, Date of Original Filed (Month/Day/Year)									Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Ž	Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea				2A. Deemed Execution Date, if any (Month/Day/Yea			Co	ansa	action (Instr.				quired (A) or) (Instr. 3, 4 and 8		5. Amount of Securities Beneficially Owned Following			: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Co	Code		An	mount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 06/15/2022				22				S	S ⁽¹⁾		5	50,000	D	\$16.2	631(2)	1,316,718		D		
Common Stock																1,000,000		I		By the 2021 Blackman Family LLC ⁽³⁾
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Month/Day/Year) if any C				4. Transaction Code (Instr. 8) Secur Acqui (A) or Dispo of (D) (Instr. and 5)			ative ities red sed 3, 4	E	6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code V (A) (I		(D)	Date D) Exercisa		ble	Expiration Date		of Shares							

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.00 to \$16.62 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the 2021 Blackman Family LLC but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.

Remarks:

/s/ Charles N. York II, as 06/17/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.